Appia Bio
Jeff Wiezorek, MD, is co-founder and CMO. He was previously senior vice president of development at Kite and led development of all CAR and TCR-engineered T cell programs including the first CAR-T therapy approved for non-Hodgkin Lymphoma. Before that, Jeff held roles of increasing responsibility over nine years at Amgen including oversight of the development teams for BLINCYTO, IMLYGIC, XGEVA, Vectibix, as well as leading the immunotherapy, angiogenesis, and bone oncology product areas encompassing Phase 1-4 clinical trials. Jeff trained in internal medicine at Stanford University and completed a fellowship in oncology at the UCLA, and did postdoctoral research with Dr. David Baltimore at Caltech. Jeff received his MD from Columbia University and a BA in biophysics from the University of Pennsylvania.
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).